Parenteral Drug Association
The Parenteral Drug Association (PDA) is an international non-profit industry trade group for pharmaceutical and biopharmaceutical manufacturers headquartered in Bethesda, MD, USA, with offices in Berlin, Germany, and Singapore.
The Parenteral Drug Association (PDA) is the leading global provider of science, technology, regulatory information, and education for the bio/pharmaceutical community. For nearly 75 years, since its founding as a non-profit in 1946, PDA has been committed to developing scientifically sound, practical technical information and resources to advance science and regulation through the expertise of our more than 10,500 members worldwide.
PDA is a truly global organization, with membership nearly equally divided between those working in the U.S. and in other regions around the world. Represented in this diverse membership is a growing number of young/early career professionals and students.
Recognized for its expertise and authority in the field of parenteral science and technology, PDA is leading the way in promoting the exchange of information on rapidly evolving technology and regulations to ensure high-quality pharmaceutical production.
PDA supports its mission to advance pharmaceutical and biopharmaceutical science and regulation so members can better serve patients by:
• Providing global forums for the scientific community, regulators, and industry professionals on emerging trends within the industry
• Delivering unique, hands-on education and training courses through PDA's manufacturing training facility
• Fostering career-long learning and professional development
• Encouraging scientific information sharing among industry peers
• Serving as a leading contributor of information and expertise to influence global industry and regulatory solutions.
PDA draws its strength from its members, which includes a corps of 2,500 active volunteers. Its conferences, meetings, and training courses, both in-person and virtual, bring together pharmaceutical manufacturers, suppliers, end users, academics, and regulatory officials for an unprecedented level of exchange on timely issues of mutual interest and concern.
Through the development of peer-reviewed Technical Reports on pressing industry topics and responses to regulatory initiatives, PDA and its members influence the future course of pharmaceutical products technology. A natural progression was for PDA to expand this expertise into the world of creating standards that provide guidance to industry on best practices for drug manufacturing for patient use. In 2017, PDA was accepted as an ANSI-accredited standards developer. PDA's first standard was published in 2020 and work is currently underway on five additional standards.
PDA's internationally recognized publications, PDA Journal of Pharmaceutical Science and Technology and PDA Letter, keep pharmaceutical manufacturing professionals up to date on the latest science and current industry and regulatory news.
Together, these activities promote the advancement of pharmaceutical science in the interest of the ultimate end-user—the patient.
PDA—Connecting People, Science, and Regulation®
Global Organization
PDA has members in 74 countries and regions:
Africa
Botswana, Egypt, Ghana, South Africa, Tunisia, Zimbabwe
Asia
Bangladesh, China, India, Pakistan
Caribbean, Central, & South America
Argentina, Brazil, Colombia, Costa Rica, Dominican Republic, Paraguay
Peru, Uruguay
Europe
Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia,
Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Latvia,
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal,
Romania, Russia, Serbia, Slovak Republic, Slovenia, Spain, Sweden, Switzerland,
Ukraine, United Kingdom
Middle East
Cyprus, Iran, Israel, Jordan, Saudi Arabia, Syria, Turkey, United
Arab Emirates
North America
Canada, Mexico, Puerto Rico, United States
Pacific-Rim
Australia, Hong Kong, Indonesia, Japan,
Malaysia, New Zealand, Singapore, South Korea,
Taiwan, Thailand, Vietnam